Bibliografia

1. Gibbs CJ Jr, Asher DM, Brown PW, Fradkin JE, Gajdusek DC. Creutzfeldt-Jakob disease infectivity of growth hormone derived from human pituitary glands. N Engl J Med. 1993; 328: 358-9.

2. Sonksen PH. Insulin, growth hormone and sport. J Endocrinol 2001; 170: 13-25.

3. Yarasheski KE, Campbell JA, Smith K, Rennie MJ, Holloszy JO, Bier DM. Effect of growth hormone and resistance exercise on muscle growth in young men. Am J Physiol 1992; 262: E261-7.

4. Deyssig R, Frisch H, Blum WF, Waldhor T. Effect of growth hormone treatment on hormonal parameters, body composition and strength in athletes. Acta Endocrinol (Copenh). 1993; 128: 313-8.

5. Lewis UJ, Sinha YN, Lewis GP. Structure and properties of members of the hGH family: a review. Endocr J 2000; 47 Suppl: S1-8.

6. Le Roith D, Bondy C, Yakar S, Liu JL, Butler A. The somatomedin hypothesis: 2001. Endocr Rev. 2001; 22: 53-74.

7. Butler AA, Le Roith D. Control of growth by the somatropic axis: growth hormone and the insulin-like growth factors have related and independent roles. Annu Rev Physiol. 2001; 63: 141-64.

8. Müller EE, Locatelli V, Cocchi D. Neuroendocrine control of growth hormone secretion. Physiol Rev. 1999; 79: 511-607.

9. Veldhuis JD, Anderson SM, Shah N et al. Neurophysiological regulation and target-tissue impact of the pulsatile mode of growth hormone secretion in the human. Growth Horm IGF Res. 2001; 11 Suppl A: S25-37.

10. Veldhuis JD. Neuroendocrine control of pulsatile growth hormone release in the human: relationship with gender. Growth Horm IGF Res. 1998; Suppl B: 49-59.

11. Corpas E, Harman SM, Blackman MR. Human growth hormone and human aging. Endocr Rev. 1993; 14: 20-39.

12. Sartorio A, Marazzi N, Agosti F et al. Elite volunteer athletes of different sport disciplines may have elevated baseline GH levels divorced from unaltered levels of both IGF-I and GH-dependent bone and collagen markers : a study on-the-field. J Endocrinol Invest. 2004; 27: 410-5.

13. Arvat E, Broglio F, Aimaretti G et al. Ghrelin and synthetic GH secretagogues. Best Pract Res Clin Endocrinol Metab. 2002; 16: 505-17.

14. Ghigo E, Arvat E, Camanni F. Orally active growth hormone secretagogues: state of the art and clinical perspectives. Ann Med. 1998; 30: 159-68.

15. Van der Lely AJ, Tschop M, Heiman ML, Ghigo E. Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev 2004 25: 426-57.

16. Micic D, Kendereski A, Popovic V et al. Growth hormone response to GHRH, GHRP-6 and GHRH + GHRP-6 in patients with polycystic ovary syndrome. Clin Endocrinol (Oxf). 1996; 45: 385-90.

17. Ghigo E, Arvat E, Aimaretti G, Broglio F, Giordano R, Camanni F. Diagnostic and therapeutic uses of growth hormone-releasing substances in adult and elderly subjects. Baillieres Clin Endocrinol Metab. 1998; 12: 341-58.

18. Maccario M, Veldhuis JD, Broglio F et al. Impact of two or three daily subcutaneous injections of hexarelin, a synthetic growth hormone (GH) secretagogue, on 24-h GH, prolactin, adrenocorticotropin and cortisol secretion in humans. Eur J Endocrinol. 2002; 146: 310-8.

19. Parker Ml, Utiger RD, Daughaday WH. Studies on human growth hormone. II. The physiological disposition and metabolic fate of human growth hormone in man. J Clin Invest. 1962; 41: 262-8.

20. Ho KY, Weissberger AJ, Stuart MC, Day RO, Lazarus L. The pharmacokinetics, safety and endocrine effects of authentic biosynthetic human growth hormone in normal subjects. Clin Endocrinol (Oxf). 1989; 30: 335-45.

21. Krogsgaard M, Friis C, Sehested B et al. Studies on the renal kinetics of growth hormone (GH) and on the GH receptor and related effects in animals. J Pediatr Endocrinol. 1994; 7: 93-105.

22. MacGillivray MH, Frohman LA, Doe J. Metabolic clearance and production rates of human growth hormone in subjects with normal and abnormal growth. J Clin Endocrinol Metab. 1970; 30: 632-8.

23. Leger J, Reverchon C, Porquet D, Noel M, Czernichow P. The wide variation in urinary excretion of human growth hormone in normal growing and growth hormone-deficient children limits its clinical usefulness. Horm Res. 1995; 44: 57-63.

24. Flanagan DE, Taylor MC, Parfitt V, Mardell R, Wood PJ, Leatherdale BA. Urinary growth hormone following exercise to assess growth hormone production in adults. Clin Endocrinol (Oxf). 1997; 46: 425-9.

25. Abramson FP, Osborn BL, Teffera Y. Isotopic differences in human growth hormone preparations. Anal Chem. 1996; 68: 1971-2.

26. Wu Z, Bidlingmaier M, Dall R, Strasburger CJ. Detection of doping with human growth hormone. Lancet. 1999; 353: 895.

27. Di Luigi L, Guidetti L. IGF-I, IGFBP-2, and -3: do they have a role in detecting rhGH abuse in trained men? Med Sci Sports Exerc. 2002; 34: 1270-8.

28. Juul A, Dalgaard P, Blum WF et al. Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation. J Clin Endocrinol Metab. 1995; 80: 2534-42.

29. Kraemer WJ, Aguilera BA, Terada M et al. Responses of IGF-I to endogenous increases in growth hormone after heavy-resistance exercise. J Appl Physiol 1995; 79: 1310-5.

30. Eliakim A, Brasel JA, Mohan S et al. Physical fitness, endurance training, and the growth hormone-insulin-like growth factor I system in adolescent females. J Clin Endocrinol Metab 1996; 81: 3986-92.

31. Harrela M, Koistinen H, Kaprio J et al Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. J Clin Invest 1996; 98: 2612-5.

32. Schwarz AJ, Brasel JA, Hintz RL, Mohan S, Cooper DM. Acute effect of brief low- and high-intensity exercise on circulating insulin-like growth factor (IGF) I, II, and IGF-binding protein-3 and its proteolysis in young healthy men. J Clin Endocrinol Metab 1996; 81: 3492-7.

33. Hornum M, Cooper DM, Brasel JA, Bueno A, Sietsema KE. Exercise-induced changes in circulating growth factors with cyclic variation in plasma estradiol in women. J Appl Physiol 1997; 82: 1946-51.

34. Longobardi S, Keay N, Ehrnborg C et al. Growth hormone (GH) effects on bone and collagen turnover in healthy adults and its potential as a marker of GH abuse in sports: a double blind, placebo-controlled study. The GH-2000 Study Group. J Clin Endocrinol Metab 2000; 85: 1505-12.

35. Wallace JD, Cuneo RC, Lundberg PA et al. Responses of markers of bone and collagen turnover to exercise, growth hormone (GH) administration, and GH withdrawal in trained adult males. J Clin Endocrinol Metab 2000; 85: 124-33.

36. Ehrnborg C, Lange KH, Dall R et al. GH-2000 Study Group. The growth hormone/insulin-like growth factor-I axis hormones and bone markers in elite athletes in response to a maximum exercise test . J Clin Endocrinol Metab 2003; 88: 394-401.

37. Sartorio A, Agosti F, Marazzi N et al. Gender-, age-, body composition- and training workload-dependent differences of GH response to a discipline-specific training session in elite athletes: a study on the field. J Endocrinol Invest 2004; 27: 121-9.

38. Di Luigi L, Rigamonti AE, Agosti F et al. Combined evaluation of resting IGF-I, N-terminal propeptide of type III procollagen and C-terminal cross-linked telopeptide of type I collagen levels might be useful for detecting inappropriate GH administration in female athletes. Eur J Endocrinol 2009; 160: 753-8.

39. Rigamonti AE, Cella SG, Marazzi N, Di Luigi L, Sartorio A, Müller EE. Growth hormone abuse: methods of detection. Trends Endocrinol Metab 2005; 16: 160-6.

40. Holt RIG, Erotokritou-Mulligan I, Cowan D et al. The GH-IGF-2012 project: the use of growth hormone (GH)-dependent markers in the detection of GH abuse in sport: intra-individual variation of IGF-I and PIIIP. In: Schänzer W, Geyer H, Gotzmann A, Marek U, eds. Recent advances in doping analysis. Proc Manfred Donike Workshop, 25 ^th Cologne Workshop on Dope Analysis, Cologne, Germany, 2007: 11-19.

41. Bennell KL, Malcolm SA, Brukner PD, Green RM, Hopper JL, Wark JD, Ebeling PR. A 12-month prospective study of the relationship between stress fractures and bone turnover in athletes. Calcif Tissue In. 1998; 63: 80-5.

42. Sartorio A, Jubeau M, Agosti F, Marazzi N, Rigamonti A, Müller EE, Maffiuletti NA. A follow-up of GH-dependent biomarkers during a 6-month period of the sporting season of male and female athletes. J Endocrinol Invest 2006; 29: 237-43.

43. Erotokritou-Mulligan I, Bassett EE, Cowan DA et al. The use of growth hormone (GH)-dependent markers in the detection of GH abuse in sport: physiological intra-individual variation of IGF-I, type 3 pro-collagen (P-III-P) and the GH-2000 detection score. Clin Endocrinol 2010; 72: 520-6.